NTLA-2001
Intellia Therapeutics
['cardio', 'cardiomyopathy', 'crispr']
a novel crispr/cas-9-based gene-editing technique seems to safely diminish the production of a protein linked to worsening outcomes in patients with transthyretin amyloidosis cardiomyopathy, according to first-in-human data. #aha22
Senior Medical Journalist @TCTMD & #FellowsForum Section Editor. Mama to a tiny human. Former @CenterHMP Media Fellow. Student of the world. All tweets my own.